Literature DB >> 20144468

The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1).

Adolfo Pedroza-Saavedra1, Eric W-F Lam, Fernando Esquivel-Guadarrama, Lourdes Gutierrez-Xicotencatl.   

Abstract

E5 oncoprotein activity from high risk human papillomaviruses (HPVs) is associated with growth factor receptor signaling, but the function of this protein is not well understood. In this study, we investigated the role of HPV-16 E5 on the cell cycle progression during EGF-stimulation. Wild-type and NIH 3T3 cells over-expressing human EGF-receptor were transfected with HPV-16 E5 gene and the cell cycle progression was characterized. This analysis showed that the E5-expressing cells increased DNA synthesis (S-phase) by around 40%. Cell cycle protein analysis of E5-expressing cells showed a reduction in the half-life of p27(Kip1) protein as compared to control cells (18.4 vs. 12.7 h), an effect that was enhanced in EGF-stimulated cells (12.8 vs. 3.6 h). Blockage of EGF-receptor activity abrogated E5 signals as well as p27(Kip1) down-regulation. These results suggest that E5 and the EGF-receptor cooperate to enhance cell cycle entry and progression through regulating p27(Kip1) expression at protein level. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20144468     DOI: 10.1016/j.virol.2010.01.009

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 2.  Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.

Authors:  Niladri Ganguly
Journal:  Cell Oncol (Dordr)       Date:  2012-01-20       Impact factor: 6.730

Review 3.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

Review 4.  Human papillomavirus infections: warts or cancer?

Authors:  Louise T Chow; Thomas R Broker
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

Review 5.  The E5 proteins.

Authors:  Daniel DiMaio; Lisa M Petti
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

6.  HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.

Authors:  Shu-Jie Liao; Dong-Rui Deng; Dan Zeng; Ling Zhang; Xiao-Ji Hu; Wei-Na Zhang; Li Li; Xue-Feng Jiang; Chang-Yu Wang; Jian-Feng Zhou; Shi-Xuan Wang; Han-Wang Zhang; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-10-20

Review 7.  The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation.

Authors:  James A Scarth; Molly R Patterson; Ethan L Morgan; Andrew Macdonald
Journal:  J Gen Virol       Date:  2021-01-11       Impact factor: 3.891

Review 8.  Papillomavirus E5: the smallest oncoprotein with many functions.

Authors:  Aldo Venuti; Francesca Paolini; Lubna Nasir; Annunziata Corteggio; Sante Roperto; Maria S Campo; Giuseppe Borzacchiello
Journal:  Mol Cancer       Date:  2011-11-11       Impact factor: 27.401

Review 9.  The role of ubiquitin and ubiquitin-like modification systems in papillomavirus biology.

Authors:  Van G Wilson
Journal:  Viruses       Date:  2014-09-24       Impact factor: 5.048

10.  CD43 promotes cells transformation by preventing merlin-mediated contact inhibition of growth.

Authors:  Nohemi Camacho-Concha; Amiel Olivos-Ortiz; Alfredo Nuñez-Rivera; Adolfo Pedroza-Saavedra; Lourdes Gutierrez-Xicotencatl; Yvonne Rosenstein; Gustavo Pedraza-Alva
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.